aniracetam has been researched along with Behavior Disorders in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease." | 2.41 | Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. ( Nakamura, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis-Reyes, BD | 1 |
| Smith, AE | 1 |
| Xu, J | 1 |
| Cunningham, KA | 1 |
| Zhou, J | 1 |
| Anastasio, NC | 1 |
| Nakamura, K | 1 |
1 review available for aniracetam and Behavior Disorders
| Article | Year |
|---|---|
Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.
Topics: Acetylcholine; Animals; Biogenic Monoamines; Brain; Brain Diseases; Cognition Disorders; Glutamic Ac | 2002 |
1 other study available for aniracetam and Behavior Disorders
| Article | Year |
|---|---|
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.
Topics: Animals; Antidepressive Agents; Cognition; Dose-Response Relationship, Drug; Glutamic Acid; Impulsiv | 2021 |